Phase II Study of Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Polatuzumab vedotin (Primary) ; Prednisone (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
- Focus Therapeutic Use
- 19 Dec 2022 Planned End Date changed from 1 Jun 2024 to 1 Sep 2026.
- 19 Dec 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Sep 2025.
- 21 Dec 2021 Status changed from not yet recruiting to recruiting.